Migraine, arterial hypertension and cerebrovascular disorders. A literature review and outcomes of candesartan (Ordiss) therapy in the prevention of migraine in patients with hypertensionстатья

Дата последнего поиска статьи во внешних источниках: 22 февраля 2019 г.

Работа с статьей

Прикрепленные файлы


Имя Описание Имя файла Размер Добавлен
1. Полный текст JNSK-08-00318.pdf 498,8 КБ 20 августа 2018 [KlimovEA]

[1] Migraine, arterial hypertension and cerebrovascular disorders. a literature review and outcomes of candesartan (ordiss) therapy in the prevention of migraine in patients with hypertension / A. Julia, S. Kirill, I. Konstantin, K. Eugene // Journal of Neurology & Stroke. — 2018. — Vol. 8, no. 4. — P. 240–243. According to current guidelines, migraine should be treated for at least 12 months. Therefore, compliance with therapy is the main prerequisite for making it successful. Yet 40% of patients receiving beta-blockers, anticonvulsants, or antidepressants refuse to continue therapy within one month, 24% to 25% are still on treatment in 6 months, and 13% to 16% take medication for 12 months. The main reason to refuse therapy, particularly during the first few weeks, is poor tolerability of these drugs (psychotropic effects, sedation, bradycardia). The goal of the study was to evaluate the efficacy and safety of candesartan (Ordiss) in patients with chronic migraine (diagnosed according to the ICHD III criteria, 2013) and hypertension (systolic blood pressure (BP) above 140 mm Hg, diastolic - above 90 mm Hg). Treatment was administered to 72 patients with chronic migraine and hypertension (9 men and 63 women, mean age 46.4±9.7 years). Efficacy was assessed using analysis of headache diary data (number of days with headache, number of days with migraine). BP levels were recorded at each visit. Assessments were performed before treatment, at 1 month, at 3 months, and at 6 months. Significant reductions were observed in the number of days with headache, from 22.3±6.0 days to 10.4±3.5 days at one month, 8.8±3.1 days at three months, and 6.2±2.7 days at six months of therapy (р<0.01 for all comparisons). There were also statistically significant reductions in the number of days with migraine: from 16.9±5.4 days prior to treatment to 7.3±2.9 days at one month, 6.5±2.7 days at three months, and 4.9±1.8 days at six months. Treatment with candesartan (Ordiss) also resulted in normalization of BP in 92.8% of the subjects. Two patients stopped treatment after experiencing general weakness and increased fatigue. Five subjects (6.9%) also reported general weakness and increased fatigue, but these events proved to be transient. Candesartan (Ordiss) can be recommended for treatment of patients with chronic migraine and hypertension. [ DOI ]

Публикация в формате сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл скрыть